{‘She lacks little experience’: the American scientific field girds for Høeg's appointment at the FDA.

Given that the United States proceeds with sweeping revisions to its vaccination schedules, one figure appears somewhat surprisingly: Høeg, a Danish American physician and epidemiologist who initially gained attention by casting doubt on Covid shots during the pandemic and has zeroed in on possible fatalities following COVID-19 immunization in her recent position at the FDA.

Scheduled Changes to Pediatric Vaccine Program

Agency leaders were set to reveal sweeping revisions to the childhood immunization program in December, aligning the US with the Danish vaccine program, sources say – a major change that would place the US at odds with a large portion of the global community with no evidence for public health gain. The announcement has been delayed until the coming year.

In place of Vinay Prasad, Høeg is set to address the audience at the gathering. She was just designated acting director of the FDA’s CDER, the fifth individual to head the division this year.

Consolidating Power at the FDA

The acting appointment could signify a closer partnership between the drug and biologics branches as Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a increased emphasis upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing some childhood vaccine recommendations in the US in order to be more in line with the Danish model, a country with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccination policy – usually the domain of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Doubts Over Background

The appointee has no apparent background in medication creation, approval processes or management, which has been typical for previous heads of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the necessary background” for running the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She’s never run a scientific study. She is not versed in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former commissioners of the center would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, said Dr. Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who headed the center have had.”

This division has an vast workload at the FDA, Woodcock pointed out.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office approves thousands of generic drugs. There’s a biosimilars program, over-the-counter program and more, and each of these need to be supervised,” she noted. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

There is also, a major leadership component to the job, which supervises over 5,000 staff members. “It’s a massive management job, if you execute it properly,” the former official added.

Response and Contentious Programs

When asked about questions about Dr. Høeg's fitness for the role and whether this assignment signifies greater collaboration among regulatory chiefs on immunizations, a representative said that the “questions stem from flawed assumptions”.

“This background matches the functions of her position,” the representative said, noting the time Dr. Høeg spent guiding the agency head on “drug safety and approval science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a disputed rapid therapy clearance system that reportedly worried her preceding directors. “By what process are these medications being picked for this fast-track system? Who is making the choices?” Howard asked. “There’s a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he stated, “the agency appears to be shifting towards more relaxed rules of most medications, aside from immunizations.”

Public Past Work on Vaccines

With vaccines, Høeg has a more established, if problematic, track record, Howard said. She released a research paper using unverified volunteer-provided data to determine the frequency of myocarditis following Covid immunization. She consulted for the state of Florida top health official Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccinations are pose a greater threat than they are.

Included in her “wish list” for the new government included altering regulations for recently developed shots and ending “optional” immunizations, she said after the election on a podcast. At the FDA, Dr. Høeg has allegedly proposed excluding teenage boys from receiving Covid vaccinations.

“She is an complete ideologue who commences with her conclusions and tailors the evidence to accommodate the science in a highly misleading, untruthful way,” Howard said.

Taking Control and a “Revenge Tour”

Høeg became part of other dissenters, {like|